Early molecular response (EMR) failure (BCR::ABL1 ≥ 10% at 3 months) is known to correlate with inferior clinical outcome and long-term MRs in CML [23, 24]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.